Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by carduon Nov 24, 2010 1:40pm

245 Views

Post# 17751939

RE: RE: RE: RE: Question. Answer

"We have to be extremely careful with the language we use, as it will be up to the regulatory bodies at the end of the day to allow us to move forward with our preferred program."

Too bad BT didn't follow Cathy's advice. He has ,over the years, suffered from foot in mouth disease. I fail to grasp why an update on enrollment in the Phase 3 trial (something he said he would "absolutely" do) can in any way be denigrated by the regulatory bodies.

I have been in ONC for eight years now and will be here until the last gasp, but that doesn't mean I have to take a pollyana approach to the management.

Bullboard Posts

Rising miner increases graphite price, restarts Québec mill